Atherosclerosis
Volume 203, Issue 2 , Pages 503-508 , April 2009

Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis

Received 7 February 2008 ,Revised 20 May 2008 ,Accepted 26 June 2008.

References 

  1. Ford ES. Giles WH Serum C-reactive protein and self reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol. 2000;20:1052–1056
  2. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscl Thromb Vasc Biol. 2000;20:1047–1051
  3. Clark WM. Cytokines and reperfusion injury. Neurology. 1997;4(suppl. 4):14
  4. Sarainen T, Carpen O, Karjialainen ML, et al. Evolution of cerebral tumor necrosis factor—a production during human ischemic stroke. Stroke. 2001;32:1750–1758
  5. Licata G, Tuttolomondo A, Corrao S, et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int J Immunopathol Pharmacol. 2006;19(3 (July–September)):639–646
  6. Lynch JR, Blessing R, White WD, Grecott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004;35:57–63
  7. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke. 1996;27:1553–1557
  8. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995;37:800–805
  9. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci. 2001;22:289–2969
  10. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–2329
  11. Fon EA, Mackey A, Cote R, et al. Hemostatic markers in acute transient ischemic attacks. Stroke. 1994;25:282–286
  12. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke. 1992;23:194–198
  13. Sato M, Suzuki A, Nagata K, Uchiyama S . Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2006 Jan;15(1):1–7
  14. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed.. John Wiley & Son, Inc.; 2000;pp. 375
  15. Efron B, Tibshirani R. Improvements on cross-validation: the bootstrap method. J Am Stat Assoc. 1997;92:548–560
  16. Yamasaki Y, Matsuura N, Shozuhara H, Omodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke. 1995;26:676–681
  17. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin 1-receptor antagonist in acute stroke. Ann Neurol. 1995;37:800–804
  18. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122:135–139
  19. Tarkowski E, Rosengren L, Bloomstrand C, et al. Early intrathecal production of interleukin-6 predicts the volume of brain lesion in stroke. Stroke. 1995;26:1393–1398
  20. Farrarese C, Mascarucci P, Zoia C, et al. Increased cytokines release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab. 1999;19:1004–1009
  21. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792–1801
  22. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34:2822–2829
  23. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost. 2001;86:138–143
  24. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499–505
  25. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135–1142
  26. De Waard V, Arkenbout EK, Carmeliet P, et al. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol. 2002;22
  27. Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31:26–32
  28. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917–925
  29. Dong JS, Fujii D, Goto T, et al. Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives. Hypertens Res. 2003;26:723
  30. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37:417–429
  31. Hu J, Ferreira A, van Eldik LJ. S100B induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem. 1997;69:2294–2301
  32. McAdory BS, van Eldik LJ, Norden JJ. S100B, a neurotrophic protein that modulates neuronal protein phosphorylation, is upregulated during esion-induced collateral sprouting and reactive synaptogenesis. Brain Res. 1998;813:211–217
  33. MacFadyen RJ. Intraindividual temporal variance of biomarkers and the definition of individualized prognosis in cardiovascular patients. J Hum Hypertens. 2006 Jun;20(6):383–386
  34. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004 Sep;148(3):462–466
  35. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003 Nov;33(11):941–948
  36. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation. 2005 Feb 22;111(7):863–870
  37. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med. 2007 Apr;261(4):384–391

PII: S0021-9150(08)00457-7

doi: 10.1016/j.atherosclerosis.2008.06.030

Atherosclerosis
Volume 203, Issue 2 , Pages 503-508 , April 2009

Article Tools